155 related articles for article (PubMed ID: 37893484)
41. Association of PSORS1C3, CARD14 and TLR4 genotypes and haplotypes with psoriasis susceptibility.
Linh NTT; Giang NH; Lien NTK; Trang BK; Trang DT; Ngoc NT; Nghia VX; My LT; Mao CV; Hoang NH; Xuan NT
Genet Mol Biol; 2022; 45(4):e20220099. PubMed ID: 36382932
[TBL] [Abstract][Full Text] [Related]
42. Aberrant Low Expression of A20 in Tumor Necrosis Factor-α-stimulated SLE Monocytes Mediates Sustained NF-κB Inflammatory Response.
Shi X; Qian T; Li M; Chen F; Chen Y; Hao F
Immunol Invest; 2015; 44(5):497-508. PubMed ID: 26107748
[TBL] [Abstract][Full Text] [Related]
43. The tumor suppressor cylindromatosis (CYLD) acts as a negative regulator for toll-like receptor 2 signaling via negative cross-talk with TRAF6 AND TRAF7.
Yoshida H; Jono H; Kai H; Li JD
J Biol Chem; 2005 Dec; 280(49):41111-21. PubMed ID: 16230348
[TBL] [Abstract][Full Text] [Related]
44. A20/Tumor Necrosis Factor α-Induced Protein 3 in Immune Cells Controls Development of Autoinflammation and Autoimmunity: Lessons from Mouse Models.
Das T; Chen Z; Hendriks RW; Kool M
Front Immunol; 2018; 9():104. PubMed ID: 29515565
[TBL] [Abstract][Full Text] [Related]
45. Paeonol alleviates placental inflammation and apoptosis in preeclampsia by inhibiting the JAK2/STAT3 signaling pathway.
Wang H; Liu ML; Chu C; Yu SJ; Li J; Shen HC; Meng Q; Zhang T
Kaohsiung J Med Sci; 2022 Nov; 38(11):1103-1112. PubMed ID: 36054229
[TBL] [Abstract][Full Text] [Related]
46. LncRNA UCA1 negatively regulates NF-kB activity in psoriatic keratinocytes through the miR125a-A20 axis.
Ma XL; Wen GD; Yu C; Zhao Z; Gao N; Liu ZY
Kaohsiung J Med Sci; 2021 Mar; 37(3):172-180. PubMed ID: 33554442
[TBL] [Abstract][Full Text] [Related]
47. Genetic factors in chronic inflammation: single nucleotide polymorphisms in the STAT-JAK pathway, susceptibility to DNA damage and Crohn's disease in a New Zealand population.
Ferguson LR; Han DY; Fraser AG; Huebner C; Lam WJ; Morgan AR; Duan H; Karunasinghe N
Mutat Res; 2010 Aug; 690(1-2):108-15. PubMed ID: 20109474
[TBL] [Abstract][Full Text] [Related]
48. [Research progress of deubiquitinating enzyme CYLD to regulate liver-related diseases].
Yang X; An DJ; Gao CC; Qin HY
Zhonghua Gan Zang Bing Za Zhi; 2019 Jun; 27(6):477-480. PubMed ID: 31357769
[TBL] [Abstract][Full Text] [Related]
49. Association of IFN-gamma signal transduction defects with impaired HLA class I antigen processing in melanoma cell lines.
Respa A; Bukur J; Ferrone S; Pawelec G; Zhao Y; Wang E; Marincola FM; Seliger B
Clin Cancer Res; 2011 May; 17(9):2668-78. PubMed ID: 21248298
[TBL] [Abstract][Full Text] [Related]
50. Cezanne regulates inflammatory responses to hypoxia in endothelial cells by targeting TRAF6 for deubiquitination.
Luong le A; Fragiadaki M; Smith J; Boyle J; Lutz J; Dean JL; Harten S; Ashcroft M; Walmsley SR; Haskard DO; Maxwell PH; Walczak H; Pusey C; Evans PC
Circ Res; 2013 Jun; 112(12):1583-91. PubMed ID: 23564640
[TBL] [Abstract][Full Text] [Related]
51. The deubiquitinase CYLD controls protective immunity against helminth infection by regulation of Treg cell plasticity.
Lee JH; Zou L; Yang R; Han J; Wan Q; Zhang X; El Baghdady S; Roman A; Elly C; Jin HS; Park Y; Croft M; Liu YC
J Allergy Clin Immunol; 2021 Jul; 148(1):209-224.e9. PubMed ID: 33309741
[TBL] [Abstract][Full Text] [Related]
52. Pathophysiological significance of cylindromatosis in the vascular endothelium and macrophages for the initiation of age-related atherogenesis.
Imaizumi Y; Takami Y; Yamamoto K; Nagasawa M; Nozato Y; Nozato S; Takeshita H; Wang C; Yokoyama S; Hayashi H; Hongyo K; Akasaka H; Takeya Y; Sugimoto K; Nakagami H; Rakugi H
Biochem Biophys Res Commun; 2019 Jan; 508(4):1168-1174. PubMed ID: 30554661
[TBL] [Abstract][Full Text] [Related]
53. Inhibition of microRNA-132 attenuates inflammatory response and detrusor fibrosis in rats with interstitial cystitis via the JAK-STAT signaling pathway.
Song YJ; Cao JY; Jin Z; Hu WG; Wu RH; Tian LH; Yang B; Wang J; Xiao Y; Huang CB
J Cell Biochem; 2019 Jun; 120(6):9147-9158. PubMed ID: 30582204
[TBL] [Abstract][Full Text] [Related]
54. JAK/STAT/SOCS-signaling pathway and colon and rectal cancer.
Slattery ML; Lundgreen A; Kadlubar SA; Bondurant KL; Wolff RK
Mol Carcinog; 2013 Feb; 52(2):155-66. PubMed ID: 22121102
[TBL] [Abstract][Full Text] [Related]
55. Kaempferol modulates IFN-γ induced JAK-STAT signaling pathway and ameliorates imiquimod-induced psoriasis-like skin lesions.
Li Y; Cui H; Li S; Li X; Guo H; Nandakumar KS; Li Z
Int Immunopharmacol; 2023 Jan; 114():109585. PubMed ID: 36527884
[TBL] [Abstract][Full Text] [Related]
56.
Yang BY; Cheng YG; Liu Y; Liu Y; Tan JY; Guan W; Guo S; Kuang HX
Molecules; 2019 Jun; 24(11):. PubMed ID: 31181689
[TBL] [Abstract][Full Text] [Related]
57. Downregulation of CYLD promotes IFN-γ mediated PD-L1 expression in thymic epithelial tumors.
Umemura S; Zhu J; Chahine JJ; Kallakury B; Chen V; Kim IK; Zhang YW; Goto K; He Y; Giaccone G
Lung Cancer; 2020 Sep; 147():221-228. PubMed ID: 32738418
[TBL] [Abstract][Full Text] [Related]
58. Loss of the tumor suppressor CYLD enhances Wnt/beta-catenin signaling through K63-linked ubiquitination of Dvl.
Tauriello DV; Haegebarth A; Kuper I; Edelmann MJ; Henraat M; Canninga-van Dijk MR; Kessler BM; Clevers H; Maurice MM
Mol Cell; 2010 Mar; 37(5):607-19. PubMed ID: 20227366
[TBL] [Abstract][Full Text] [Related]
59. English version of Japanese guidance for the use of oral Janus kinase inhibitors (JAK1 and TYK2 inhibitors) in the treatments of psoriasis.
Saeki H; Mabuchi T; Asahina A; Abe M; Igarashi A; Imafuku S; Okubo Y; Komine M; Takahashi K; Torii H; Morita A; Yotsuyanagi H; Watanabe A; Ohtsuki M;
J Dermatol; 2023 May; 50(5):e138-e150. PubMed ID: 37132187
[TBL] [Abstract][Full Text] [Related]
60. CYLD deubiquitinates RIP1 in the TNFα-induced necrosome to facilitate kinase activation and programmed necrosis.
Moquin DM; McQuade T; Chan FK
PLoS One; 2013; 8(10):e76841. PubMed ID: 24098568
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
